drug
efanesoctocog alfa
Marketedupdated 6mo agoby Bioverativ Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(1)
Trials studying efanesoctocog alfa
- phase4Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- phase4Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
- phase3Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
- phase1Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
- —Goal Attainment and Physical Activity in People With Hemophilia A
- phase4A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
- phase3A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
- —A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
News(4)
- Sanofi targets late-phase and commercial M&A to offset looming Dupixent declineFocused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported thi…biospace · 19d ago
- Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 pushSobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.fiercebiotech · 3mo ago
- Chutes & Ladders—BioNTech brings in Sobi CEOAfter a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the…fiercebiotech · 3mo ago
- After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA companyOne of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.fiercebiotech · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that